Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.53 USD

73.53
8,119,563

+0.23 (0.31%)

Updated Jul 18, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q4 Earnings?

by Sweta Killa

With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $63.43, marking a +1.28% move from the previous day.

GILD or EXEL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GILD vs. EXEL: Which Stock Is the Better Value Option?

Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

by Zacks Equity Research

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

Nektar's Pain Drug Gets Adverse Advisory Committee Decision

by Zacks Equity Research

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $64.31, moving -1.11% from the previous trading session.

The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor

Sheraz Mian headshot

Stock Research Reports for Chevron, Accenture, Adobe & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Accenture (ACN) and Adobe Systems (ADBE).

Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

by Zacks Equity Research

Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

by Zacks Equity Research

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $65.12, marking a -0.81% move from the previous day.

Novo Nordisk's Shares Up in a Year on Pipeline Progress

by Zacks Equity Research

Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.

GILD vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GILD vs. TECH: Which Stock Is the Better Value Option?

Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down

by Zacks Equity Research

Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.

    Gilead (GILD) Partners With Eisai for RA Candidate in Japan

    by Zacks Equity Research

    Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.

    Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed the most recent trading day at $66.72, moving -0.04% from the previous trading session.

    GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA

    by Zacks Equity Research

    GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.

    Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib

    by Zacks Equity Research

    Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.

    The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

    Ekta Bagri headshot

    Biotech Stock Outlook: M&A Activity Retains Growth Streak

    by Ekta Bagri

    The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.

    Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

    by Zacks Equity Research

    The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.

    Gilead (GILD) Announces Top-Line Results From NASH Study

    by Zacks Equity Research

    Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.

    Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed at $66.12 in the latest trading session, marking a +0.53% move from the prior day.

    Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy

    by Zacks Equity Research

    Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.

    Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

    by Zacks Equity Research

    The biotech sector witnesses pipeline updates from the annual ASH meet.